NCT02611518View on ClinicalTrials.gov

A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 5, 2016

Primary Completion Date

June 14, 2016

Study Completion Date

June 14, 2016

Conditions
Healthy
Interventions
DRUG

Rosuvastatin

Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.

DRUG

JNJ-54861911

JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).

DRUG

Metformin

Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.

Trial Locations (1)

Unknown

Berlin

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02611518 - A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants | Biotech Hunter | Biotech Hunter